-
A simple 24-week oral regimen consisting of
sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated
people with genotype 1 hepatitis C, many of whom had factors predictive of poor
response, researchers
reported last week
at the 20th Conference
on Retroviruses and Opportunistic Infections ...
20 March 2013 | Liz Highleyman
-
All-oral regimens consisting of the HCV protease
inhibitor ABT-450, a non-nucleoside polymerase inhibitor and ribavirin led to
sustained response for more than 90% of previously untreated hepatitis C patients – including those with unfavourable IL28B gene
patterns – but ...
20 March 2013 | Liz Highleyman
-
Moderate alcohol consumption - as little as one or two drinks per day - is associated
with an increased risk of mortality for people with chronic hepatitis C virus
(HCV) infection, according to research conducted in the United ...
18 March 2013 | Michael Carter
-
Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the
duration of treatment and increases the likelihood of a cure for HIV-positive
men with acute sexually transmitted hepatitis C virus (HCV), according to study
findings presented last ...
12 March 2013 | Liz Highleyman
-
An all-oral combination of
simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for
most hard-to-treat prior null responders with genotype 1 hepatitis C studied in
the phase 2a COSMOS trial, according to a presentation last ...
12 March 2013 | Liz Highleyman
-
Adding the hepatitis C virus
(HCV) protease inhibitor faldaprevir (formerly BI 201335) to pegylated interferon and
ribavirin led to a higher early response rate and the potential for shorter
treatment for HIV/HCV co-infected people, according to a presentation last ...
11 March 2013 | Liz Highleyman
-
Adding the new hepatitis C
virus (HCV) protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and
ribavirin cures about three-quarters of HIV/HCV co-infected people, most of
them with a shortened course of therapy, researchers reported last week at the ...
11 March 2013 | Liz Highleyman
-
Adding boceprevir or
telaprevir to interferon-based therapy showed promising indications of efficacy
and acceptable safety for difficult-to-treat HIV/HCV co-infected prior
non-responders in a pair of French studies presented yesterday at the 20th Conference
on Retroviruses and Opportunistic Infections (CROI
2013) in Atlanta.The advent
of ...
05 March 2013 | Liz Highleyman
-
An interferon-free regimen containing
sofosbuvir (formerly GS-7997), ledipasvir (formerly GS-5885) and ribavirin
produced a 12-week post-treatment sustained virological response (SVR12) rate
of 100% for both treatment-naive hepatitis C patients and prior interferon non-responders,
according to data presented yesterday at the ...
05 March 2013 | Liz Highleyman
-
Spanish research published in the online
edition of Clinical Infectious Diseases
shows the benefits of successful hepatitis C therapy for people co-infected
with HIV who have compensated liver cirrhosis. Achievement of a sustained
virological response (SVR) was associated with lower ...
28 February 2013 | Michael Carter
Get set for HIV treatmentA tool to help you decide whether you are ready to start taking HIV treatment.
HIV, GPs & other primary careThis booklet explains the services GPs offer, how this fits with HIV specialist care, and how to make the most of primary care services.
Treatment as prevention – free webinar 20 March 2013As
part of its European HIV prevention work, NAM is collaborating...
Microbicides research – free webinar 22 February 2013As
part of its European HIV prevention work, NAM is collaborating...
HIV treatment update – Winter 2013 21 February 2013The new edition of HIV treatment update (HTU) is on...